Study of cases of abiraterone discontinuation due to toxicity in pre-chemotherapy after 1 year’s experience

Abiraterone acetate is a potent and irreversible inhibitor of cytochrome p450 17A1 that suppresses androgen synthesis. It is approved for chemotherapy-naive and docetaxel-treated patients with metastatic castration-resistant prostate cancer. We describe the protocol for use of abiraterone in metasta...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of oncology pharmacy practice 2017-12, Vol.23 (8), p.615-619
Hauptverfasser:	Ramudo-Cela, Luis, Balea-Filgueiras, Jesús, Vizoso-Hermida, José Ramón, Martín-Herranz, Isabel
Format:	Artikel
Sprache:	eng
Schlagworte:	Abiraterone Acetate - adverse effects Abiraterone Acetate - therapeutic use Aged, 80 and over Androstenes - adverse effects Androstenes - therapeutic use Disease Progression Humans Male Middle Aged Prostatic Neoplasms, Castration-Resistant - blood Prostatic Neoplasms, Castration-Resistant - diagnosis Prostatic Neoplasms, Castration-Resistant - drug therapy Safety-Based Drug Withdrawals - trends Taxoids - adverse effects Taxoids - therapeutic use Time Factors Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!